Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Astellas Pharma Inc    4503   JP3942400007

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Astellas Pharma : Transfer of Distribution Rights for Targocid® and Maalox®

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/09/2011 | 04:10am CET

Astellas Pharma Inc. (“Astellas Pharma”; Headquarters: Chuo-ku, Tokyo; President and CEO: Yoshihiko Hatanaka) and sanofi-aventis K.K. (“sanofi-aventis”; Headquarters: Shinjuku-ku, Tokyo; Representative Director and President: Jez Moulding) announced that Astellas Pharma will transfer the rights to distribute the injectable antibiotics Targocid® (generic name: teicoplanin) and the treatment for peptic ulcer and gastritis Maalox® (generic name: dried aluminum hydroxide gel and magnesium hydroxide) to sanofi-aventis effective on January 1, 2012. This transfer of distribution rights is taking place based on the expiration of the contract.

<Products for which distribution rights will be transferred>

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTELLAS PHARMA INC
01/20 ASTELLAS PHARMA : Improves Rank in Second Year Named to Corporate Knights' 2017 ..
01/19 ASTELLAS PHARMA : Improves Rank in Second Year Named to Corporate Knights’..
01/18 ASTELLAS PHARMA : Announces Participation in Access Accelerated - Builds on Comp..
01/12 ASTELLAS PHARMA : Launches Second Phase of Global Campaign on CNN
01/10 ASTELLAS PHARMA : Terminates Agreement with UMN Pharma for Cell Culture Based In..
2016 ASTELLAS PHARMA : Completes Acquisition of Ganymed Pharmaceuticals
2016 ASTELLAS PHARMA : to Present at J.P. Morgan Healthcare Conference
2016 ASTELLAS PHARMA : Announces FDA Fast Track Designation for ASP0892, DNA Vaccine ..
2016 ASTELLAS PHARMA : Notice of Completion of Acquisition of Own Shares
2016 ASTELLAS PHARMA : Notice of Completion of Acquisition of Own Shares
More news
Sector news : Pharmaceuticals - NEC
01/20 European shares ease ahead of Trump inauguration
01/20 Bristol-Myers shares fall on lung cancer timeline setback
01/19DJRival to EpiPen Allergy Treatment to Return to Market--Update
01/19DJRival to EpiPen Allergy Treatment to Return to Market
01/19 Davos CEOs 'go local' on supply chain in Trump era
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01/10 ObsEva Initiates IPO Filing For Women's Reproductive Treatments
01/10 RHEUMATOID ARTHRITIS : The Big 3 And The Future
2016 Akebia Gets High With Second Japanese Partner
2016 FDA annouces fast track designation for Astellas' ASP0892 for reactions due t..
2016 Marketing application filed in Japan for osteoporosis candidate romosozumab
Advertisement
Financials ( JPY)
Sales 2017 1 320 948 M
EBIT 2017 275 000 M
Net income 2017 201 824 M
Finance 2017 471 719 M
Yield 2017 2,23%
P/E ratio 2017 16,12
P/E ratio 2018 15,27
EV / Sales 2017 2,16x
EV / Sales 2018 1,98x
Capitalization 3 329 811 M
More Financials
Chart ASTELLAS PHARMA INC
Duration : Period :
Astellas Pharma Inc Technical Analysis Chart | 4503 | JP3942400007 | 4-Traders
Full-screen chart
Technical analysis trends ASTELLAS PHARMA INC
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 1 937  JPY
Spread / Average Target 25%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Yoshihiko Hatanaka President, CEO & Representative Director
Masafumi Nogimori Chairman
Yasumasa Masuda Chief Financial Officer
Mitsunori Matsuda Senior Executive Officer & President-Technology
Yoshiro Miyokawa Representative Director & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC-5.04%28 996
JOHNSON & JOHNSON-0.88%310 685
ROCHE HOLDING LTD.1.29%200 208
PFIZER INC.-2.40%192 367
NOVARTIS AG-3.71%185 489
MERCK & CO., INC.2.48%166 338
More Results